Byetta (Exenatide Injection)
What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Coming Soon – Save up to 85%
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prescription Required
-
Product Details
Description
Byetta is a prescription medication used to improve blood sugar control in adults with type 2 diabetes mellitus. It contains the active ingredient exenatide, a synthetic version of a hormone called incretin, which enhances the body's ability to regulate blood sugar levels.
Byetta is not insulin but works by stimulating the pancreas to increase insulin levels when blood sugar is high. It also reduces the amount of sugar produced by the liver and slows down the rate at which food empties from the stomach, helping to control appetite and reduce food intake.
Fact Table
Formula
C184H282N50O60S
License
US FDA, EMA
Bioavailability
~65% (subcutaneous)
Legal status
Prescription only (?)
Chemical Name
Exenatide
Elimination half-life
2.4 hours
Dosage (Strength)
5 mcg, 10 mcg per dose (injection pen)
Pregnancy
Use with caution
Brands
Byetta, Bydureon (extended-release)
Protein binding
Not significant
PubChem CID
16134945
MedlinePlus
a605034
ChEBI
CHEBI:72338
ATC code
A10BJ01
DrugBank
DB01276
KEGG
D04628
Routes of administration
Subcutaneous
Directions
The usual directions are to inject 5-10 micrograms under the skin twice daily. The dose should be about 12 hours apart.
Ingredients
The active ingredient in Byetta is exenatide.
Interactions
Common drug-drug interactions may include:
- Abiraterone Acetate
- Acebutolol
- Atenolol
- Betaxolol
- Bisoprolol
- Carteolol
- Carvedilol
- Celiprolol
- Chloroquine
- Chlorothiazide
- Chlorthalidone
- Ciprofloxacin
- Delafloxacin
- Digoxin
- Enoxacin
- Esmolol
- Furosemide
- Gatifloxacin
- Gemifloxacin
- Glecaprevir
- Grepafloxacin
- Hydrochlorothiazide
- Hydroflumethiazide
- Hydroxychloroquine
- Indapamide
- Insulin
- Insulin Aspart, Recombinant
- Insulin Bovine
- Insulin Degludec
- Insulin Detemir
- Insulin Glargine, Recombinant
- Insulin Glulisine
- Insulin Lispro, Recombinant
- Labetalol
- Lanreotide Acetate
- Levofloxacin
- Levobunolol
- Lomefloxacin
- Metipranolol
- Metolazone
- Metoprolol
- Moxifloxacin
- Nadolol
- Nebivolol
- Norfloxacin
- Octreotide Acetate
- Ofloxacin
- Oxprenolol
- Pasireotide Diaspartate
- Penbutolol
- Pibrentasvir
- Pindolol
- Polythiazide
- Practolol
- Propranolol
- Semaglutide
- Somatrogon-ghla
- Sotalol
- Sparfloxacin
- Thioctic Acid
- Timolol
- Triamterene
- Trovafloxacin
- Warfarin
Cautions
Byetta should be used with caution in patients with severe gastrointestinal (GI) diseases, such as gastroparesis, due to its effect on gastric emptying.
Byetta is not recommended for patients with type 1 diabetes or diabetic ketoacidosis.
Patients with a history of pancreatitis should use Byetta with caution, as it has been associated with reports of acute pancreatitis.
Side Effects
The most common side effects include:
- Abnormal renal function
- Acute hemorrhagic pancreatitis
- Acute renal failure
- Angioedema
- Anaphylaxis
- Antibody development
- Asthenia
- Constipation
- Dehydration
- Diarrhea
- Dizziness
- Feeling nervous
- Headache
- Hypersensitivity reaction
- Hypoglycemia
- Injection site disorder
- Injection site mass
- Injection site pruritus
- Indigestion
- Medullary thyroid carcinoma
- Nausea
- Necrotizing pancreatitis, acute
- Pancreatic cancer
- Pancreatitis, acute
- Thrombocytopenia
- Vomiting
References
Byetta [package insert]. San Diego, CA: Amylin; October 2009.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 9339
-
Product Reviews
